Intratumoral Bacterial Burden Drives Immunotherapy Resistance in Head and Neck Cancer
oncodaily - Immune checkpoint blockade (ICB) benefits only a subset of patients with head and neck squamous cell carcinoma (HNSCC), and commonly used biomarkers (PD-L1, TMB) remain imperfect in this setting. This […]
AI Summary: Researchers reveal that an increased bacterial burden within head and neck tumors may undermine the efficacy of immune checkpoint blockade treatments. Detailed investigations indicate that intratumoral bacteria could be a pivotal factor in treatment resistance, opening new avenues for overcoming these challenges in managing advanced head and neck cancers.
Related Stories
Therapeutic HPV vaccine slows throat tumors in preclinical tests / 4 months
Gene‑editing trials explore one‑time fix for high cholesterol / 4 months
Bayer’s Asundexian Reduces Stroke Risk by 26% in Phase 3 Trial / 5 months
Eikon Therapeutics raises $381M IPO for cancer drug advancement / 5 months
Aktis Oncology IPO boosts radiopharmaceutical pipeline / 6 months
Giredestrant lowers recurrence risk in early-stage breast cancer / 7 months
Protego Bio Secures $130M for AL Amyloidosis Therapy Development / 7 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Health Disparities, Venture Capital, Hearing Loss, Gene Therapy and look for the RSS link.
StackHealth Time Machine